- Fulgent Genetics press release ( NASDAQ: FLGT ): Q4 Non-GAAP EPS of -$0.48 beats by $0.08 .
- Revenue of $67.7M (-73.1% Y/Y) beats by $8.13M .
- Core Revenue grew 97% year-over-year to $55.0 million
-
For the first quarter of 2023, Fulgent expects:
- Total Revenue of approximately $56.0 million vs. $60.93M consesus
For the full year 2023, Fulgent expects:
- Total Revenue of approximately $240.0 million vs. $260.76M consensus
- GAAP loss of approximately $2.50 per share
- Non-GAAP loss of approximately $1.25 per share vs. -$2.18 consensus
For further details see:
Fulgent Genetics Non-GAAP EPS of -$0.48 beats by $0.08, revenue of $67.7M beats by $8.13M